| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Clever Leaves Holdings Inc. (NASDAQ:CLVR) (NADAQ:CLVRW) has entered into a five-year agreement with Hypera Pharma (B3:HYPE3) to supply Clever Leaves’ CBD-dominant oral solutions with the aim of treating various medical conditions and prescribing to Brazilian patients.
Hypera Pharma is one of Brazil’s largest pharmaceutical companies in net sales with expertise in the registration, commercialization, and distribution of prescription medicines as well as over-the-counter and skin care products. The CBD products manufactured under this partnership have been registered under RDC 327 framework and are already being sold into distribution channels such as pharmacies and drugstores. The companies plan to continue the process with additional products.
“Hypera Pharma’s history, innovative vision, capabilities, focus on high-quality, and commitment to sustainable growth is aligned with Clever Leaves’ values, making them an ideal partner to promote and scale patient access to safe, pharmaceutical-grade cannabis products in Brazil. Expanding our presence in Brazil, a market that prioritizes patient treatment by enabling research and development to ensure technical and quality standards, will open doors for potential new developments and is further evidence of how our platform can support the global pharmaceutical industry by allowing it to engage in the world of cannabis-based therapies with patient safety and product quality at the forefront,” stated Andres Fajardo, CEO of Clever Leaves.
Photo: Benzinga edit with photos by Matthias Zomer on Pexels, squarefrog on Pixabay
Related News
Clever Leaves And Praetorian Team Up To Produce Cannabis Genetics In Colombia
Clever Leaves Reports Fourth Quarter And Full Year 2022 Results
